Nerve growth factor
This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Nerve growth factor | |
|---|---|
 | |
| Name | Nerve growth factor |
| Organism | Homo sapiens |
Nerve growth factor is a secreted protein that regulates survival, growth, differentiation, and maintenance of specific neuronal populations and non-neuronal cells. It is central to peripheral sensory and sympathetic neuron development and influences functions in the central nervous system, immune system, and endocrine organs. Major research into its roles has involved collaboration among laboratories at institutions such as Harvard University, Stanford University, National Institutes of Health, Max Planck Society, and Cold Spring Harbor Laboratory.
Overview
Nerve growth factor was first identified as a trophic factor essential for the survival of developing neurons in experimental systems used by scientists at Rockefeller University, Columbia University, and University of Cambridge. Studies spanning investigators from University of Chicago, Yale University, University of California, San Francisco, Massachusetts Institute of Technology, and University College London demonstrated NGF's capacity to promote axonal growth and to modulate synaptic plasticity. Clinical and translational research groups at Mayo Clinic, Johns Hopkins University, Karolinska Institutet, and University of Oxford have explored its relevance to neurodegeneration, pain, and regenerative medicine.
Structure and Biosynthesis
NGF is synthesized as a precursor protein, pro-NGF, which undergoes post-translational cleavage to yield the mature homodimeric protein studied in biochemistry labs at California Institute of Technology, ETH Zurich, Princeton University, and Imperial College London. Structural analyses using techniques developed at European Molecular Biology Laboratory, Riken, and Brookhaven National Laboratory revealed disulfide-bonded domains and folding motifs that resemble other members of the neurotrophin family characterized by researchers at University of Pennsylvania and University of Michigan. Biosynthetic pathways implicate processing enzymes investigated by teams at Scripps Research Institute, University of Toronto, University of Basel, and National Cancer Institute.
Receptors and Signaling Pathways
NGF exerts effects primarily through high-affinity receptor tyrosine kinase TrkA and the low-affinity p75 neurotrophin receptor, receptor biology examined at University of California, Los Angeles, Vanderbilt University, University of North Carolina at Chapel Hill, and McGill University. TrkA activation triggers intracellular cascades including Ras-MAPK, PI3K-Akt, and PLCγ signaling elucidated by researchers at Cold Spring Harbor Laboratory, Howard Hughes Medical Institute, European Bioinformatics Institute, and Institute Pasteur. p75 modulates apoptosis and survival via interactions with sortilin and other co-receptors studied at Karolinska Institutet, Weizmann Institute, and University of Edinburgh. Cross-talk between TrkA and p75 influences outcomes in models developed at Duke University, University of Washington, and University of Texas Southwestern Medical Center.
Physiological Roles
NGF supports development of peripheral sensory neurons and sympathetic neurons characterized in animal models at Princeton University, University of Pennsylvania, Cornell University, and University of California, Berkeley. It modulates nociception, inflammation, and immune cell function studied at Johns Hopkins School of Medicine, Mount Sinai Health System, and Columbia University Irving Medical Center. In the central nervous system, NGF influences cholinergic neurons of the basal forebrain with implications investigated by teams at Massachusetts General Hospital, University of Cambridge, Imperial College London, and University of Toronto. Roles in wound healing and endocrine regulation have been explored by researchers at University of Melbourne, University of Sydney, and National University of Singapore.
Clinical Significance and Therapeutic Applications
Altered NGF signaling is implicated in conditions such as peripheral neuropathy, chronic pain syndromes, and neurodegenerative disorders studied at clinical centers including Mayo Clinic, Cleveland Clinic, UCLA Medical Center, and Brigham and Women's Hospital. Monoclonal antibodies targeting NGF were developed in pharmaceutical programs at Pfizer, Eli Lilly and Company, Novartis, and Regeneron Pharmaceuticals to treat osteoarthritis pain; clinical trials coordinated with regulatory agencies like the Food and Drug Administration and European Medicines Agency assessed efficacy and safety. Gene therapy and recombinant NGF delivery strategies were evaluated in translational research at Astellas Pharma, GlaxoSmithKline, Takeda Pharmaceutical Company, and academic centers including University College London and Harvard Medical School. Biomarker and imaging studies integrating work from NIH Clinical Center, Stanford Medicine, and Toronto General Hospital aim to stratify patients for NGF-directed interventions.
History of Discovery and Research Developments
The discovery and characterization of NGF involved pioneering investigators affiliated with Rockefeller University, University of Chicago, Columbia University, and University of Cambridge whose work influenced prize-awarding bodies such as the Nobel Prize committees that recognized contributions to neurobiology. Subsequent waves of research advanced structural biology at European Molecular Biology Laboratory and Riken, cell signaling at Howard Hughes Medical Institute labs, and clinical translation through collaborations with pharmaceutical companies in Basel, Cambridge (UK), and Boston. Contemporary developments integrate multidisciplinary teams across National Institutes of Health, Wellcome Trust, European Commission, and private foundations to refine therapeutic strategies and to map NGF-related pathways in health and disease.
Category:Neurotrophic factors